Tumor-selective high LET and high RBE particles can overcome the radiation-resistant glioma stem cells

肿瘤选择性高LET和高RBE颗粒可以克服抗辐射胶质瘤干细胞

• 批准号: 23390355
• 负责人: MIYATAKE Shin-Ichi
• 金额: $ 11.98万
• 依托单位: Osaka Medical College
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 2011
• 资助国家: 日本
• 起止时间: 2011-04-01 至 2014-03-31
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23390355/
• 关键词: high LET; BNCT; glioma stem cell; 放射線抵抗性; 癌幹細胞; 放射線; X線; 粒子線; グリオーマ幹細胞; 高ＬＥＴ粒子線; ほう素中性子捕捉療法; 高LET放射線治療

GSLC were induced from GBM cell line A172. The phenotypes of GSLCs were confirmed by stem cell markers. These cells were irradiated with 60Co gamma rays or reactor neutron beams. Under neutron beam irradiation, high-LET proton particles can be produced. Radiosensitivity was assessed by a CFA, and the DNA double-strand breaks (DSBs) were assessed by gamma-H2AX focus assay. In stem cell culture medium, GSLCs could form neurosphere-like cells and express neural stem cell markers, Sox2 and Musashi, abundantly in comparison with their parental cells. GSLCs were significantly more radioresistant to gamma rays than their parental cells, but neutron beams overcame this resistance. Twenty-four hours after irradiation with gamma rays, there were significantly fewer gamma-H2AX foci in A172 GSLCs than in their parental cultured cells, while there was no apparent difference following neutron beam irradiation. High-LET radiation can overcome the radioresistance of GSLCs.

从GBM细胞系A172诱导GSLC。GSLCs的表型通过干细胞标志物证实。这些电池用60 Co γ射线或反应堆中子束辐照。在中子束辐照下，可以产生高LET质子粒子。用CFA评价放射敏感性，用γ-H2 AX聚焦试验评价DNA双链断裂（DSB）。在干细胞培养液中，GSLCs可以形成神经球样细胞，并表达神经干细胞标志物Sox 2和Musashi，与其亲本细胞相比，表达丰富。GSLCs对伽马射线的抵抗力明显高于其亲本细胞，但中子束克服了这种抵抗力。γ射线照射后24 h，A172 GSLCs中γ-H2 AX灶明显少于其亲本培养细胞，而中子束照射后无明显差异。高LET辐射可以克服GSLCs的辐射抗性。

项目成果

Symptomatic Radiation Necrosis Diagnosed by Amino Acid PET Motomasa Furuse

氨基酸 PET Motomasa Furuse 诊断症状性放射性坏死

• 发表时间: 2013
• 期刊: Bevacizumab Treatment for Jpn J Clin Oncol
• 作者: Naosuke Nonoguchi;Shinji Kawabata;Erina Yoritsune;Masatsugu Takahashi;Taisuke Inomata;Toshihiko Kuroiwa and Shin-Ichi Miyatake
• 通讯作者: Toshihiko Kuroiwa and Shin-Ichi Miyatake

薬事承認を目指した多施設共同研究, 第3項先進医療「症候性脳放射線壊死の核医学的診断とベバシズマブの静脈内投与による治療」日本脳神経外科学会

日本神经外科学会以药品批准为目标的多中心联合研究第3部先进医疗“症状性脑放射性坏死的核医学诊断和贝伐单抗静脉给药治疗”

• 发表时间: 2013
• 作者: 宮武伸一;他16 名
• 通讯作者: 他16 名

高度医療（第3項先進医療）「症候性脳放射線壊死に対する核医学的診断とベバシズマブの静脈内投与による治療」について

先进医疗（第3节先进医疗）“症状性脑放射性坏死的核医学诊断和贝伐单抗静脉给药治疗”

• 发表时间: 2011
• 作者: Miyake J;Shimada K;Oka K;Tanaka H;Sugamoto K;Yoshikawa H;Murase T.;宮武伸一
• 通讯作者: 宮武伸一

「症候性脳放射線壊死の核医学的診断とベバシズマブの静脈内投与による治療」薬事承認を目指した多施設共同研究

“症状性脑放射性坏死的核医学诊断及贝伐珠单抗静脉注射治疗”多中心联合研究拟获监管批准

• 发表时间: 2013
• 作者: 宮武伸一;他16 名
• 通讯作者: 他16 名

Bevacizumab treatment of symptomatic pseudoprogression after boron neutron capture therapy for recurrent malignant gliomas. Report of 2 cases

• DOI: 10.1093/neuonc/not020
• 发表时间: 2013-06-01
• 期刊: NEURO-ONCOLOGY
• 影响因子: 15.9
• 作者: Miyatake, Shin-Ichi;Furuse, Motomasa;Ono, Koji
• 通讯作者: Ono, Koji